Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia
Recruiting now
Conditions studied: Hidradenitis Suppurativa (HS)
In brief
This study aims to assess the treatment satisfaction of HS patients newly started on secukinumab in Saudi Arabia, in terms of patient reported convenience, perceived safety, perceived effectiveness and global treatment satisfaction as measured by the treatment satisfaction questionnaire for medication (TSQM) at week 24 among moderate to severe HS patients.
Key facts
- Study ID
- NCT06785779
- Run by
- Novartis Pharmaceuticals
- People needed
- 77
- Starts
- 2025-03-10
- Expected to finish
- 2026-09-30
- Last updated by the study team
- 2025-12-30
Who can join
Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male or Female adult patients ≥18 years of age at the time of data collection.
- Patient with a confirmed diagnosis of active moderate to severe HS.
- Secukinumab naive patients (first dose to coincide within one month of the signature of the informed consent) as per locally approved label.
- Patients can be using antibiotics or have undergone surgery as per routine clinical practice.
- Patients agree to sign an informed consent form (ICF) to be able to complete the questionnaires.
You may not qualify if…
- Patients not fulfilling any of the above-mentioned inclusion criteria.
- Patient's refusal to be included in the study or refusal to sign the ICF.
- A history of off-label indication uses of biological treatment or JAK inhibitor.
Where it is running
- Novartis Investigative Site — Riyadh, SAU, Saudi Arabia (enrolling)
- Novartis Investigative Site — Jeddah, Saudi Arabia (enrolling)
- Novartis Investigative Site — Jeddah, Saudi Arabia (enrolling)
- Novartis Investigative Site — Riyadh, Saudi Arabia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.